Abstract:Backgroud: The co-administration of Chinese patent medicine with calcium channel blockers (CCBs) is a prevalent practice in China for treating essential hypertension (EH). However, robust evidence supporting the efficacy and safety of tailored combinations of different Chinese patent medicines with CCBs, according to individual patient conditions, is still limited. This study sought to elucidate the efficacy and safety of these combinations using a systematic review and network meta-analysis. Materials and methods: Relevant studies were sourced from established databases, incorporating randomized controlled trials published up to 1 February 2023. The ROB2 tool from the Cochrane Collaborative Network was employed to independently assess and cross-verify the quality of the included literature. A network meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 and PRISMA-Network Meta-Analyses (PRISMA-NMA) guidelines. A Bayesian network meta-analysis was utilized to gauge the efficacy and safety of distinct integrations of Chinese patent medicine and CCBs. Primary outcomes were interpreted using a paired fixed-effect meta-analysis. Publication bias was appraised through Egger's test and represented with funnel plots. All statistical analyses were executed within the R statistical framework. Results: Following rigorous selection, data extraction, and bias evaluation, 36 articles were incorporated. Tianma Gouteng Granule, when combined with CCBs, displayed superior efficacy in reducing systolic blood pressure (SBP). In terms of diastolic blood pressure (DBP) reduction, Songling Xuemaikang Capsule combined with CCBs emerged as the most effective. Regarding enhancement of antihypertensive effective rates, Qinggan Jiangya Capsule paired with CCBs demonstrated optimal results. For diminishing Traditional Chinese Medicine syndrome scores, the Qiangli Dingxuan Tablet and CCBs combination proved most beneficial. When aiming to reduce total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, Tianma Gouteng Granule and CCBs showcased superior results. In contrast, the combination of Songling Xuemaikang Capsule and CCBs was more effective in reducing LDL-C, tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). Conclusion: This study underscores variability in outcomes from combining Chinese patent medicine and CCBs for hypertension, emphasizing the importance of personalized medicinal combinations, especially Tianma Gouteng Granule and Songling Xuemaikang Capsule. The results offer robust evidence to inform clinical guidelines for essential hypertention and significantly aid clinician in seleting appropriate Chinese patent medicines for treatment.

[Impact of CACNA1C Polymorphisms on Antihypertensive Efficacy of Calcium Channel Blocker].

Study on the Correlation Between CETP TaqIB,KCNE1 S38G and Enos T-786C Gene Polymorphisms for Predisposition and Non-Valvular Atrial Fibrillation

The Kcnh2 Genetic Polymorphism (1956, C > T) Is A Novel Biomarker That Is Associated With Ccb And Alpha,Beta-Adr Blocker Response In Eh Patients In China

Impact of Genetic Polymorphism of SDF1 3A on Efficacy of Captopril in Chinese Patients with Essential Hypertension

Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment.

Association of Calca Genetic Polymorphism with Essential Hypertension

Impact of 14 Types of Genetic Polymorphisms on Antihypertensive Efficacy of Felodipine in Healthy Chinese Subjects

Effect of Nedd4l Gene Five Common Polymorphisms on Hypertension-Related Phenotypes in Han Chinese Hypertension Patients

Association analysis between genetic polymorphism of ADD-1 gene and GNB3 gene and essential hypertension

Influence of G-protein Β-Polypeptide 3 C825T Polymorphism on Antihypertensive Response to Telmisartan and Amlodipine in Chinese Patients.

Study on the relationship between the therapeutic effect of enalapril on blood pressure reduction and ACE genetic polymorphisms

Influence of PRKCH Gene Polymorphism on Antihypertensive Response to Amlodipine and Telmisartan

Correlation of the SCNN1A Gene Polymorphism and the Essential Hypertension in Tujia, Miao and Han Chinese

Combined Effects of the Rs9810888 Polymorphism in Calcium Voltage-Gated Channel Subunit Alpha1 D (CACNA1D) and Lifestyle Behaviors on Blood Pressure Level among Chinese Children.

Relationship between CYP17A1 Genetic Polymorphism and Essential Hypertension in a Chinese Population.

Functional Polymorphisms in Epithelial Na Channel γ Subunit and Neural Precursor Cell Expressed Developmentally Down Regulated 4-like Gene and Essential Hypertension in Uyghur Population

Association of Polymorphisms in Prolylcarboxypeptidase and Chymase Genes with Essential Hypertension in the Chinese Han Population

Associations between polymorphisms of the CXCL12 and CNNM2 gene and hypertension risk: A case-control study

Polymorphisms Within Angiotensin Ii Receptor Type 1 Gene Associated with Essential Hypertension in Chinese Hani and Yi Minorities

Common Polymorphism Rs11191548 Near the Cyp17a1 Gene is Associated with Hypertension and Systolic Blood Pressure in the Han Chinese Population

Chinese patent medicine combined with calcium channel blockers in the treatment of essential hypertension:a Bayes network meta-analysis and systematic review